Company Description
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.
It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC.
The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No.
3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp.
SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.
The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Country | United States |
| Founded | 1999 |
| IPO Date | May 2, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 28 |
| CEO | David Angulo |
Contact Details
Address: 1 Evertrust Plaza, 13th Floor Jersey City, New Jersey 07302-6548 United States | |
| Phone | 201 884 5485 |
| Website | scynexis.com |
Stock Details
| Ticker Symbol | SCYX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178253 |
| CUSIP Number | 811292200 |
| ISIN Number | US8112922005 |
| Employer ID | 56-2181648 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Gonzalez Angulo M.D. | Chief Executive Officer, President and Director |
| Ivor Macleod CPA, M.B.A. | Chief Financial Officer |
| Scott Sukenick J.D. | Chief Legal Officer and Corporate Secretary |
| Daniella Gigante | Vice President of Human Resources and Information Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 8, 2025 | SCHEDULE 13G/A | Filing |
| Dec 18, 2024 | 144 | Filing |
| Dec 18, 2024 | 144 | Filing |
| Dec 18, 2024 | 144 | Filing |
| Dec 11, 2024 | 144 | Filing |
| Dec 11, 2024 | 144 | Filing |
| Dec 11, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |